Global PSMA-labeled Imaging Ligands Market Growth 2026-2032
The global PSMA-labeled Imaging Ligands market size is predicted to grow from US$ 2784 million in 2025 to US$ 12246 million in 2032; it is expected to grow at a CAGR of 24.2% from 2026 to 2032.
Prostate-specific membrane antigen (PSMA)-labeled ligands refer to small-molecule compounds that target PSMA and are conjugated with diagnostic radionuclides (primarily Gallium-68 and Fluorine-18) for PET imaging, enabling lesion detection, staging evaluation, and pre-therapeutic patient selection in prostate cancer; they do not deliver therapeutic radiation doses and are classified as radiodiagnostic agents, typically serving as a prerequisite step for PSMA-RLT. The PSMA-labeled ligand market is transitioning from early commercialization to rapid expansion, with a global effective addressable market (EAM) of approximately $2.846 billion in 2025 (including $1.679 billion in commercialized market and $1.0?1.5 billion in convertible in-house demand), corresponding to an annual scan volume of 1.5?2.0 million and a CAGR of 23.3%. Growth is primarily driven by the expansion of F-18 industrialized distribution networks in the U.S. and increasing demand for patient selection alongside broader PSMA-RLT penetration, while the Chinese market remains in an early-stage expansion phase driven by infrastructure build-out.
On the supply side, nominal ?capacity? is essentially the combination of radiopharmacy network coverage and hospital nuclear medicine processing capabilities, where the Fluorine-18 system offers superior scalability through centralized cyclotron production and distribution networks, while the Gallium-68 system is constrained by generator availability and in-house operational capacity, resulting in a decentralized supply structure. In terms of pricing, F-18 finished radiopharmaceuticals (represented by Pylarify) are priced at approximately $3,000?5,000 per dose, while Ga-68 kit-based usage corresponds to $1,000?3,000 per dose; the industry overall exhibits high gross margins of 70?85% (with higher margins for kits but smaller revenue pools). Downstream applications are highly concentrated in the prostate cancer diagnostic workflow (initial staging ? recurrence detection ? RLT selection), with demand increasingly shifting toward pre-therapy selection as PSMA-targeted therapies expand. The value chain consists of upstream radionuclide supply (F-18, Ga-68 generators) and ligand synthesis, midstream radiopharmaceutical production and distribution networks (a centralized model led by Lantheus Holdings coexisting with a kit-based model led by Telix Pharmaceuticals), and downstream nuclear medicine departments and imaging centers. The global competitive landscape is characterized by an ?F-18 oligopoly + Ga-68 dual-core? structure (industrial distribution dominated by Lantheus Holdings, and kit-based pathways led by Novartis and Telix Pharmaceuticals). The industry is fundamentally in a growth stage where demand has been validated but commercialization penetration remains incomplete, driven by the migration from in-house preparation to industrialized distribution and RLT-driven diagnostic demand, while the key uncertainty lies in logistical delivery radius and nuclear medicine infrastructure constraints on F-18 penetration.
LP Information, Inc. (LPI) ' newest research report, the ?PSMA-labeled Imaging Ligands Industry Forecast? looks at past sales and reviews total world PSMA-labeled Imaging Ligands sales in 2025, providing a comprehensive analysis by region and market sector of projected PSMA-labeled Imaging Ligands sales for 2026 through 2032. With PSMA-labeled Imaging Ligands sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PSMA-labeled Imaging Ligands industry.
This Insight Report provides a comprehensive analysis of the global PSMA-labeled Imaging Ligands landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PSMA-labeled Imaging Ligands portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global PSMA-labeled Imaging Ligands market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PSMA-labeled Imaging Ligands and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PSMA-labeled Imaging Ligands.
This report presents a comprehensive overview, market shares, and growth opportunities of PSMA-labeled Imaging Ligands market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global PSMA-labeled Imaging Ligands market?
What factors are driving PSMA-labeled Imaging Ligands market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do PSMA-labeled Imaging Ligands market opportunities vary by end market size?
How does PSMA-labeled Imaging Ligands break out by Type, by Application?
Prostate-specific membrane antigen (PSMA)-labeled ligands refer to small-molecule compounds that target PSMA and are conjugated with diagnostic radionuclides (primarily Gallium-68 and Fluorine-18) for PET imaging, enabling lesion detection, staging evaluation, and pre-therapeutic patient selection in prostate cancer; they do not deliver therapeutic radiation doses and are classified as radiodiagnostic agents, typically serving as a prerequisite step for PSMA-RLT. The PSMA-labeled ligand market is transitioning from early commercialization to rapid expansion, with a global effective addressable market (EAM) of approximately $2.846 billion in 2025 (including $1.679 billion in commercialized market and $1.0?1.5 billion in convertible in-house demand), corresponding to an annual scan volume of 1.5?2.0 million and a CAGR of 23.3%. Growth is primarily driven by the expansion of F-18 industrialized distribution networks in the U.S. and increasing demand for patient selection alongside broader PSMA-RLT penetration, while the Chinese market remains in an early-stage expansion phase driven by infrastructure build-out.
On the supply side, nominal ?capacity? is essentially the combination of radiopharmacy network coverage and hospital nuclear medicine processing capabilities, where the Fluorine-18 system offers superior scalability through centralized cyclotron production and distribution networks, while the Gallium-68 system is constrained by generator availability and in-house operational capacity, resulting in a decentralized supply structure. In terms of pricing, F-18 finished radiopharmaceuticals (represented by Pylarify) are priced at approximately $3,000?5,000 per dose, while Ga-68 kit-based usage corresponds to $1,000?3,000 per dose; the industry overall exhibits high gross margins of 70?85% (with higher margins for kits but smaller revenue pools). Downstream applications are highly concentrated in the prostate cancer diagnostic workflow (initial staging ? recurrence detection ? RLT selection), with demand increasingly shifting toward pre-therapy selection as PSMA-targeted therapies expand. The value chain consists of upstream radionuclide supply (F-18, Ga-68 generators) and ligand synthesis, midstream radiopharmaceutical production and distribution networks (a centralized model led by Lantheus Holdings coexisting with a kit-based model led by Telix Pharmaceuticals), and downstream nuclear medicine departments and imaging centers. The global competitive landscape is characterized by an ?F-18 oligopoly + Ga-68 dual-core? structure (industrial distribution dominated by Lantheus Holdings, and kit-based pathways led by Novartis and Telix Pharmaceuticals). The industry is fundamentally in a growth stage where demand has been validated but commercialization penetration remains incomplete, driven by the migration from in-house preparation to industrialized distribution and RLT-driven diagnostic demand, while the key uncertainty lies in logistical delivery radius and nuclear medicine infrastructure constraints on F-18 penetration.
LP Information, Inc. (LPI) ' newest research report, the ?PSMA-labeled Imaging Ligands Industry Forecast? looks at past sales and reviews total world PSMA-labeled Imaging Ligands sales in 2025, providing a comprehensive analysis by region and market sector of projected PSMA-labeled Imaging Ligands sales for 2026 through 2032. With PSMA-labeled Imaging Ligands sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PSMA-labeled Imaging Ligands industry.
This Insight Report provides a comprehensive analysis of the global PSMA-labeled Imaging Ligands landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PSMA-labeled Imaging Ligands portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global PSMA-labeled Imaging Ligands market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PSMA-labeled Imaging Ligands and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PSMA-labeled Imaging Ligands.
This report presents a comprehensive overview, market shares, and growth opportunities of PSMA-labeled Imaging Ligands market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Gallium-68?Ga-68?
- Fluorine-18?F-18?
- Ready-to-use Drug
- Kit-based Radiolabeling
- Initial Staging
- Biochemical Recurrence
- Theranostics Selection
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Lantheus Holdings
- Novartis
- Curium
- Blue Earth Diagnostics
- Bayer
- Advanced Biochemical Compounds(ABX)
- Yantai Dongcheng
- China Isotope & Radiation
- Grand Pharmaceutical
- Telix Pharmaceuticals
What is the 10-year outlook for the global PSMA-labeled Imaging Ligands market?
What factors are driving PSMA-labeled Imaging Ligands market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do PSMA-labeled Imaging Ligands market opportunities vary by end market size?
How does PSMA-labeled Imaging Ligands break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global PSMA-labeled Imaging Ligands Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for PSMA-labeled Imaging Ligands by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for PSMA-labeled Imaging Ligands by Country/Region, 2021, 2025 & 2032
2.2 PSMA-labeled Imaging Ligands Segment by Type
2.2.1 Gallium-68?Ga-68?
2.2.2 Fluorine-18?F-18?
2.2.3 PSMA-labeled Imaging Ligands Sales by Type
2.2.3.1 Global PSMA-labeled Imaging Ligands Sales Market Share by Type (2021-2026)
2.2.3.2 Global PSMA-labeled Imaging Ligands Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global PSMA-labeled Imaging Ligands Sale Price by Type (2021-2026)
2.3 PSMA-labeled Imaging Ligands Segment by Dosage
2.3.1 Ready-to-use Drug
2.3.2 Kit-based Radiolabeling
2.3.3 PSMA-labeled Imaging Ligands Sales by Dosage
2.3.3.1 Global PSMA-labeled Imaging Ligands Sales Market Share by Dosage (2021-2026)
2.3.3.2 Global PSMA-labeled Imaging Ligands Revenue and Market Share by Dosage (2021-2026)
2.3.3.3 Global PSMA-labeled Imaging Ligands Sale Price by Dosage (2021-2026)
2.4 PSMA-labeled Imaging Ligands Segment by Application
2.4.1 Initial Staging
2.4.2 Biochemical Recurrence
2.4.3 Theranostics Selection
2.4.4 Others
2.4.5 PSMA-labeled Imaging Ligands Sales by Application
2.4.5.1 Global PSMA-labeled Imaging Ligands Sale Market Share by Application (2021-2026)
2.4.5.2 Global PSMA-labeled Imaging Ligands Revenue and Market Share by Application (2021-2026)
2.4.5.3 Global PSMA-labeled Imaging Ligands Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global PSMA-labeled Imaging Ligands Breakdown Data by Company
3.1.1 Global PSMA-labeled Imaging Ligands Annual Sales by Company (2021-2026)
3.1.2 Global PSMA-labeled Imaging Ligands Sales Market Share by Company (2021-2026)
3.2 Global PSMA-labeled Imaging Ligands Annual Revenue by Company (2021-2026)
3.2.1 Global PSMA-labeled Imaging Ligands Revenue by Company (2021-2026)
3.2.2 Global PSMA-labeled Imaging Ligands Revenue Market Share by Company (2021-2026)
3.3 Global PSMA-labeled Imaging Ligands Sale Price by Company
3.4 Key Manufacturers PSMA-labeled Imaging Ligands Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PSMA-labeled Imaging Ligands Product Location Distribution
3.4.2 Players PSMA-labeled Imaging Ligands Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PSMA-LABELED IMAGING LIGANDS BY GEOGRAPHIC REGION
4.1 World Historic PSMA-labeled Imaging Ligands Market Size by Geographic Region (2021-2026)
4.1.1 Global PSMA-labeled Imaging Ligands Annual Sales by Geographic Region (2021-2026)
4.1.2 Global PSMA-labeled Imaging Ligands Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic PSMA-labeled Imaging Ligands Market Size by Country/Region (2021-2026)
4.2.1 Global PSMA-labeled Imaging Ligands Annual Sales by Country/Region (2021-2026)
4.2.2 Global PSMA-labeled Imaging Ligands Annual Revenue by Country/Region (2021-2026)
4.3 Americas PSMA-labeled Imaging Ligands Sales Growth
4.4 APAC PSMA-labeled Imaging Ligands Sales Growth
4.5 Europe PSMA-labeled Imaging Ligands Sales Growth
4.6 Middle East & Africa PSMA-labeled Imaging Ligands Sales Growth
5 AMERICAS
5.1 Americas PSMA-labeled Imaging Ligands Sales by Country
5.1.1 Americas PSMA-labeled Imaging Ligands Sales by Country (2021-2026)
5.1.2 Americas PSMA-labeled Imaging Ligands Revenue by Country (2021-2026)
5.2 Americas PSMA-labeled Imaging Ligands Sales by Type (2021-2026)
5.3 Americas PSMA-labeled Imaging Ligands Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PSMA-labeled Imaging Ligands Sales by Region
6.1.1 APAC PSMA-labeled Imaging Ligands Sales by Region (2021-2026)
6.1.2 APAC PSMA-labeled Imaging Ligands Revenue by Region (2021-2026)
6.2 APAC PSMA-labeled Imaging Ligands Sales by Type (2021-2026)
6.3 APAC PSMA-labeled Imaging Ligands Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe PSMA-labeled Imaging Ligands by Country
7.1.1 Europe PSMA-labeled Imaging Ligands Sales by Country (2021-2026)
7.1.2 Europe PSMA-labeled Imaging Ligands Revenue by Country (2021-2026)
7.2 Europe PSMA-labeled Imaging Ligands Sales by Type (2021-2026)
7.3 Europe PSMA-labeled Imaging Ligands Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa PSMA-labeled Imaging Ligands by Country
8.1.1 Middle East & Africa PSMA-labeled Imaging Ligands Sales by Country (2021-2026)
8.1.2 Middle East & Africa PSMA-labeled Imaging Ligands Revenue by Country (2021-2026)
8.2 Middle East & Africa PSMA-labeled Imaging Ligands Sales by Type (2021-2026)
8.3 Middle East & Africa PSMA-labeled Imaging Ligands Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PSMA-labeled Imaging Ligands
10.3 Manufacturing Process Analysis of PSMA-labeled Imaging Ligands
10.4 Industry Chain Structure of PSMA-labeled Imaging Ligands
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PSMA-labeled Imaging Ligands Distributors
11.3 PSMA-labeled Imaging Ligands Customer
12 WORLD FORECAST REVIEW FOR PSMA-LABELED IMAGING LIGANDS BY GEOGRAPHIC REGION
12.1 Global PSMA-labeled Imaging Ligands Market Size Forecast by Region
12.1.1 Global PSMA-labeled Imaging Ligands Forecast by Region (2027-2032)
12.1.2 Global PSMA-labeled Imaging Ligands Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global PSMA-labeled Imaging Ligands Forecast by Type (2027-2032)
12.7 Global PSMA-labeled Imaging Ligands Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Lantheus Holdings
13.1.1 Lantheus Holdings Company Information
13.1.2 Lantheus Holdings PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.1.3 Lantheus Holdings PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Lantheus Holdings Main Business Overview
13.1.5 Lantheus Holdings Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.2.3 Novartis PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Curium
13.3.1 Curium Company Information
13.3.2 Curium PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.3.3 Curium PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Curium Main Business Overview
13.3.5 Curium Latest Developments
13.4 Blue Earth Diagnostics
13.4.1 Blue Earth Diagnostics Company Information
13.4.2 Blue Earth Diagnostics PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.4.3 Blue Earth Diagnostics PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Blue Earth Diagnostics Main Business Overview
13.4.5 Blue Earth Diagnostics Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.5.3 Bayer PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 Advanced Biochemical Compounds(ABX)
13.6.1 Advanced Biochemical Compounds(ABX) Company Information
13.6.2 Advanced Biochemical Compounds(ABX) PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.6.3 Advanced Biochemical Compounds(ABX) PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Advanced Biochemical Compounds(ABX) Main Business Overview
13.6.5 Advanced Biochemical Compounds(ABX) Latest Developments
13.7 Yantai Dongcheng
13.7.1 Yantai Dongcheng Company Information
13.7.2 Yantai Dongcheng PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.7.3 Yantai Dongcheng PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Yantai Dongcheng Main Business Overview
13.7.5 Yantai Dongcheng Latest Developments
13.8 China Isotope & Radiation
13.8.1 China Isotope & Radiation Company Information
13.8.2 China Isotope & Radiation PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.8.3 China Isotope & Radiation PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 China Isotope & Radiation Main Business Overview
13.8.5 China Isotope & Radiation Latest Developments
13.9 Grand Pharmaceutical
13.9.1 Grand Pharmaceutical Company Information
13.9.2 Grand Pharmaceutical PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.9.3 Grand Pharmaceutical PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Grand Pharmaceutical Main Business Overview
13.9.5 Grand Pharmaceutical Latest Developments
13.10 Telix Pharmaceuticals
13.10.1 Telix Pharmaceuticals Company Information
13.10.2 Telix Pharmaceuticals PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.10.3 Telix Pharmaceuticals PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Telix Pharmaceuticals Main Business Overview
13.10.5 Telix Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global PSMA-labeled Imaging Ligands Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for PSMA-labeled Imaging Ligands by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for PSMA-labeled Imaging Ligands by Country/Region, 2021, 2025 & 2032
2.2 PSMA-labeled Imaging Ligands Segment by Type
2.2.1 Gallium-68?Ga-68?
2.2.2 Fluorine-18?F-18?
2.2.3 PSMA-labeled Imaging Ligands Sales by Type
2.2.3.1 Global PSMA-labeled Imaging Ligands Sales Market Share by Type (2021-2026)
2.2.3.2 Global PSMA-labeled Imaging Ligands Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global PSMA-labeled Imaging Ligands Sale Price by Type (2021-2026)
2.3 PSMA-labeled Imaging Ligands Segment by Dosage
2.3.1 Ready-to-use Drug
2.3.2 Kit-based Radiolabeling
2.3.3 PSMA-labeled Imaging Ligands Sales by Dosage
2.3.3.1 Global PSMA-labeled Imaging Ligands Sales Market Share by Dosage (2021-2026)
2.3.3.2 Global PSMA-labeled Imaging Ligands Revenue and Market Share by Dosage (2021-2026)
2.3.3.3 Global PSMA-labeled Imaging Ligands Sale Price by Dosage (2021-2026)
2.4 PSMA-labeled Imaging Ligands Segment by Application
2.4.1 Initial Staging
2.4.2 Biochemical Recurrence
2.4.3 Theranostics Selection
2.4.4 Others
2.4.5 PSMA-labeled Imaging Ligands Sales by Application
2.4.5.1 Global PSMA-labeled Imaging Ligands Sale Market Share by Application (2021-2026)
2.4.5.2 Global PSMA-labeled Imaging Ligands Revenue and Market Share by Application (2021-2026)
2.4.5.3 Global PSMA-labeled Imaging Ligands Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global PSMA-labeled Imaging Ligands Breakdown Data by Company
3.1.1 Global PSMA-labeled Imaging Ligands Annual Sales by Company (2021-2026)
3.1.2 Global PSMA-labeled Imaging Ligands Sales Market Share by Company (2021-2026)
3.2 Global PSMA-labeled Imaging Ligands Annual Revenue by Company (2021-2026)
3.2.1 Global PSMA-labeled Imaging Ligands Revenue by Company (2021-2026)
3.2.2 Global PSMA-labeled Imaging Ligands Revenue Market Share by Company (2021-2026)
3.3 Global PSMA-labeled Imaging Ligands Sale Price by Company
3.4 Key Manufacturers PSMA-labeled Imaging Ligands Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PSMA-labeled Imaging Ligands Product Location Distribution
3.4.2 Players PSMA-labeled Imaging Ligands Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PSMA-LABELED IMAGING LIGANDS BY GEOGRAPHIC REGION
4.1 World Historic PSMA-labeled Imaging Ligands Market Size by Geographic Region (2021-2026)
4.1.1 Global PSMA-labeled Imaging Ligands Annual Sales by Geographic Region (2021-2026)
4.1.2 Global PSMA-labeled Imaging Ligands Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic PSMA-labeled Imaging Ligands Market Size by Country/Region (2021-2026)
4.2.1 Global PSMA-labeled Imaging Ligands Annual Sales by Country/Region (2021-2026)
4.2.2 Global PSMA-labeled Imaging Ligands Annual Revenue by Country/Region (2021-2026)
4.3 Americas PSMA-labeled Imaging Ligands Sales Growth
4.4 APAC PSMA-labeled Imaging Ligands Sales Growth
4.5 Europe PSMA-labeled Imaging Ligands Sales Growth
4.6 Middle East & Africa PSMA-labeled Imaging Ligands Sales Growth
5 AMERICAS
5.1 Americas PSMA-labeled Imaging Ligands Sales by Country
5.1.1 Americas PSMA-labeled Imaging Ligands Sales by Country (2021-2026)
5.1.2 Americas PSMA-labeled Imaging Ligands Revenue by Country (2021-2026)
5.2 Americas PSMA-labeled Imaging Ligands Sales by Type (2021-2026)
5.3 Americas PSMA-labeled Imaging Ligands Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PSMA-labeled Imaging Ligands Sales by Region
6.1.1 APAC PSMA-labeled Imaging Ligands Sales by Region (2021-2026)
6.1.2 APAC PSMA-labeled Imaging Ligands Revenue by Region (2021-2026)
6.2 APAC PSMA-labeled Imaging Ligands Sales by Type (2021-2026)
6.3 APAC PSMA-labeled Imaging Ligands Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe PSMA-labeled Imaging Ligands by Country
7.1.1 Europe PSMA-labeled Imaging Ligands Sales by Country (2021-2026)
7.1.2 Europe PSMA-labeled Imaging Ligands Revenue by Country (2021-2026)
7.2 Europe PSMA-labeled Imaging Ligands Sales by Type (2021-2026)
7.3 Europe PSMA-labeled Imaging Ligands Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa PSMA-labeled Imaging Ligands by Country
8.1.1 Middle East & Africa PSMA-labeled Imaging Ligands Sales by Country (2021-2026)
8.1.2 Middle East & Africa PSMA-labeled Imaging Ligands Revenue by Country (2021-2026)
8.2 Middle East & Africa PSMA-labeled Imaging Ligands Sales by Type (2021-2026)
8.3 Middle East & Africa PSMA-labeled Imaging Ligands Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PSMA-labeled Imaging Ligands
10.3 Manufacturing Process Analysis of PSMA-labeled Imaging Ligands
10.4 Industry Chain Structure of PSMA-labeled Imaging Ligands
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PSMA-labeled Imaging Ligands Distributors
11.3 PSMA-labeled Imaging Ligands Customer
12 WORLD FORECAST REVIEW FOR PSMA-LABELED IMAGING LIGANDS BY GEOGRAPHIC REGION
12.1 Global PSMA-labeled Imaging Ligands Market Size Forecast by Region
12.1.1 Global PSMA-labeled Imaging Ligands Forecast by Region (2027-2032)
12.1.2 Global PSMA-labeled Imaging Ligands Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global PSMA-labeled Imaging Ligands Forecast by Type (2027-2032)
12.7 Global PSMA-labeled Imaging Ligands Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Lantheus Holdings
13.1.1 Lantheus Holdings Company Information
13.1.2 Lantheus Holdings PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.1.3 Lantheus Holdings PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Lantheus Holdings Main Business Overview
13.1.5 Lantheus Holdings Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.2.3 Novartis PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Curium
13.3.1 Curium Company Information
13.3.2 Curium PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.3.3 Curium PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Curium Main Business Overview
13.3.5 Curium Latest Developments
13.4 Blue Earth Diagnostics
13.4.1 Blue Earth Diagnostics Company Information
13.4.2 Blue Earth Diagnostics PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.4.3 Blue Earth Diagnostics PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Blue Earth Diagnostics Main Business Overview
13.4.5 Blue Earth Diagnostics Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.5.3 Bayer PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 Advanced Biochemical Compounds(ABX)
13.6.1 Advanced Biochemical Compounds(ABX) Company Information
13.6.2 Advanced Biochemical Compounds(ABX) PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.6.3 Advanced Biochemical Compounds(ABX) PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Advanced Biochemical Compounds(ABX) Main Business Overview
13.6.5 Advanced Biochemical Compounds(ABX) Latest Developments
13.7 Yantai Dongcheng
13.7.1 Yantai Dongcheng Company Information
13.7.2 Yantai Dongcheng PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.7.3 Yantai Dongcheng PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Yantai Dongcheng Main Business Overview
13.7.5 Yantai Dongcheng Latest Developments
13.8 China Isotope & Radiation
13.8.1 China Isotope & Radiation Company Information
13.8.2 China Isotope & Radiation PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.8.3 China Isotope & Radiation PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 China Isotope & Radiation Main Business Overview
13.8.5 China Isotope & Radiation Latest Developments
13.9 Grand Pharmaceutical
13.9.1 Grand Pharmaceutical Company Information
13.9.2 Grand Pharmaceutical PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.9.3 Grand Pharmaceutical PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Grand Pharmaceutical Main Business Overview
13.9.5 Grand Pharmaceutical Latest Developments
13.10 Telix Pharmaceuticals
13.10.1 Telix Pharmaceuticals Company Information
13.10.2 Telix Pharmaceuticals PSMA-labeled Imaging Ligands Product Portfolios and Specifications
13.10.3 Telix Pharmaceuticals PSMA-labeled Imaging Ligands Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Telix Pharmaceuticals Main Business Overview
13.10.5 Telix Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. PSMA-labeled Imaging Ligands Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. PSMA-labeled Imaging Ligands Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Gallium-68?Ga-68?
Table 4. Major Players of Fluorine-18?F-18?
Table 5. Global PSMA-labeled Imaging Ligands Sales by Type (2021-2026) & (Units)
Table 6. Global PSMA-labeled Imaging Ligands Sales Market Share by Type (2021-2026)
Table 7. Global PSMA-labeled Imaging Ligands Revenue by Type (2021-2026) & ($ million)
Table 8. Global PSMA-labeled Imaging Ligands Revenue Market Share by Type (2021-2026)
Table 9. Global PSMA-labeled Imaging Ligands Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Ready-to-use Drug
Table 11. Major Players of Kit-based Radiolabeling
Table 12. Global PSMA-labeled Imaging Ligands Sales by Dosage (2021-2026) & (Units)
Table 13. Global PSMA-labeled Imaging Ligands Sales Market Share by Dosage (2021-2026)
Table 14. Global PSMA-labeled Imaging Ligands Revenue by Dosage (2021-2026) & ($ million)
Table 15. Global PSMA-labeled Imaging Ligands Revenue Market Share by Dosage (2021-2026)
Table 16. Global PSMA-labeled Imaging Ligands Sale Price by Dosage (2021-2026) & (US$/Unit)
Table 17. Global PSMA-labeled Imaging Ligands Sale by Application (2021-2026) & (Units)
Table 18. Global PSMA-labeled Imaging Ligands Sale Market Share by Application (2021-2026)
Table 19. Global PSMA-labeled Imaging Ligands Revenue by Application (2021-2026) & ($ million)
Table 20. Global PSMA-labeled Imaging Ligands Revenue Market Share by Application (2021-2026)
Table 21. Global PSMA-labeled Imaging Ligands Sale Price by Application (2021-2026) & (US$/Unit)
Table 22. Global PSMA-labeled Imaging Ligands Sales by Company (2021-2026) & (Units)
Table 23. Global PSMA-labeled Imaging Ligands Sales Market Share by Company (2021-2026)
Table 24. Global PSMA-labeled Imaging Ligands Revenue by Company (2021-2026) & ($ millions)
Table 25. Global PSMA-labeled Imaging Ligands Revenue Market Share by Company (2021-2026)
Table 26. Global PSMA-labeled Imaging Ligands Sale Price by Company (2021-2026) & (US$/Unit)
Table 27. Key Manufacturers PSMA-labeled Imaging Ligands Producing Area Distribution and Sales Area
Table 28. Players PSMA-labeled Imaging Ligands Products Offered
Table 29. PSMA-labeled Imaging Ligands Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 30. New Products and Potential Entrants
Table 31. Market M&A Activity & Strategy
Table 32. Global PSMA-labeled Imaging Ligands Sales by Geographic Region (2021-2026) & (Units)
Table 33. Global PSMA-labeled Imaging Ligands Sales Market Share Geographic Region (2021-2026)
Table 34. Global PSMA-labeled Imaging Ligands Revenue by Geographic Region (2021-2026) & ($ millions)
Table 35. Global PSMA-labeled Imaging Ligands Revenue Market Share by Geographic Region (2021-2026)
Table 36. Global PSMA-labeled Imaging Ligands Sales by Country/Region (2021-2026) & (Units)
Table 37. Global PSMA-labeled Imaging Ligands Sales Market Share by Country/Region (2021-2026)
Table 38. Global PSMA-labeled Imaging Ligands Revenue by Country/Region (2021-2026) & ($ millions)
Table 39. Global PSMA-labeled Imaging Ligands Revenue Market Share by Country/Region (2021-2026)
Table 40. Americas PSMA-labeled Imaging Ligands Sales by Country (2021-2026) & (Units)
Table 41. Americas PSMA-labeled Imaging Ligands Sales Market Share by Country (2021-2026)
Table 42. Americas PSMA-labeled Imaging Ligands Revenue by Country (2021-2026) & ($ millions)
Table 43. Americas PSMA-labeled Imaging Ligands Sales by Type (2021-2026) & (Units)
Table 44. Americas PSMA-labeled Imaging Ligands Sales by Application (2021-2026) & (Units)
Table 45. APAC PSMA-labeled Imaging Ligands Sales by Region (2021-2026) & (Units)
Table 46. APAC PSMA-labeled Imaging Ligands Sales Market Share by Region (2021-2026)
Table 47. APAC PSMA-labeled Imaging Ligands Revenue by Region (2021-2026) & ($ millions)
Table 48. APAC PSMA-labeled Imaging Ligands Sales by Type (2021-2026) & (Units)
Table 49. APAC PSMA-labeled Imaging Ligands Sales by Application (2021-2026) & (Units)
Table 50. Europe PSMA-labeled Imaging Ligands Sales by Country (2021-2026) & (Units)
Table 51. Europe PSMA-labeled Imaging Ligands Revenue by Country (2021-2026) & ($ millions)
Table 52. Europe PSMA-labeled Imaging Ligands Sales by Type (2021-2026) & (Units)
Table 53. Europe PSMA-labeled Imaging Ligands Sales by Application (2021-2026) & (Units)
Table 54. Middle East & Africa PSMA-labeled Imaging Ligands Sales by Country (2021-2026) & (Units)
Table 55. Middle East & Africa PSMA-labeled Imaging Ligands Revenue Market Share by Country (2021-2026)
Table 56. Middle East & Africa PSMA-labeled Imaging Ligands Sales by Type (2021-2026) & (Units)
Table 57. Middle East & Africa PSMA-labeled Imaging Ligands Sales by Application (2021-2026) & (Units)
Table 58. Key Market Drivers & Growth Opportunities of PSMA-labeled Imaging Ligands
Table 59. Key Market Challenges & Risks of PSMA-labeled Imaging Ligands
Table 60. Key Industry Trends of PSMA-labeled Imaging Ligands
Table 61. PSMA-labeled Imaging Ligands Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. PSMA-labeled Imaging Ligands Distributors List
Table 64. PSMA-labeled Imaging Ligands Customer List
Table 65. Global PSMA-labeled Imaging Ligands Sales Forecast by Region (2027-2032) & (Units)
Table 66. Global PSMA-labeled Imaging Ligands Revenue Forecast by Region (2027-2032) & ($ millions)
Table 67. Americas PSMA-labeled Imaging Ligands Sales Forecast by Country (2027-2032) & (Units)
Table 68. Americas PSMA-labeled Imaging Ligands Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. APAC PSMA-labeled Imaging Ligands Sales Forecast by Region (2027-2032) & (Units)
Table 70. APAC PSMA-labeled Imaging Ligands Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 71. Europe PSMA-labeled Imaging Ligands Sales Forecast by Country (2027-2032) & (Units)
Table 72. Europe PSMA-labeled Imaging Ligands Revenue Forecast by Country (2027-2032) & ($ millions)
Table 73. Middle East & Africa PSMA-labeled Imaging Ligands Sales Forecast by Country (2027-2032) & (Units)
Table 74. Middle East & Africa PSMA-labeled Imaging Ligands Revenue Forecast by Country (2027-2032) & ($ millions)
Table 75. Global PSMA-labeled Imaging Ligands Sales Forecast by Type (2027-2032) & (Units)
Table 76. Global PSMA-labeled Imaging Ligands Revenue Forecast by Type (2027-2032) & ($ millions)
Table 77. Global PSMA-labeled Imaging Ligands Sales Forecast by Application (2027-2032) & (Units)
Table 78. Global PSMA-labeled Imaging Ligands Revenue Forecast by Application (2027-2032) & ($ millions)
Table 79. Lantheus Holdings Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 80. Lantheus Holdings PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 81. Lantheus Holdings PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Lantheus Holdings Main Business
Table 83. Lantheus Holdings Latest Developments
Table 84. Novartis Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 85. Novartis PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 86. Novartis PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Novartis Main Business
Table 88. Novartis Latest Developments
Table 89. Curium Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 90. Curium PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 91. Curium PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Curium Main Business
Table 93. Curium Latest Developments
Table 94. Blue Earth Diagnostics Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 95. Blue Earth Diagnostics PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 96. Blue Earth Diagnostics PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Blue Earth Diagnostics Main Business
Table 98. Blue Earth Diagnostics Latest Developments
Table 99. Bayer Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 100. Bayer PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 101. Bayer PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Bayer Main Business
Table 103. Bayer Latest Developments
Table 104. Advanced Biochemical Compounds(ABX) Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 105. Advanced Biochemical Compounds(ABX) PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 106. Advanced Biochemical Compounds(ABX) PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Advanced Biochemical Compounds(ABX) Main Business
Table 108. Advanced Biochemical Compounds(ABX) Latest Developments
Table 109. Yantai Dongcheng Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 110. Yantai Dongcheng PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 111. Yantai Dongcheng PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Yantai Dongcheng Main Business
Table 113. Yantai Dongcheng Latest Developments
Table 114. China Isotope & Radiation Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 115. China Isotope & Radiation PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 116. China Isotope & Radiation PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. China Isotope & Radiation Main Business
Table 118. China Isotope & Radiation Latest Developments
Table 119. Grand Pharmaceutical Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 120. Grand Pharmaceutical PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 121. Grand Pharmaceutical PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Grand Pharmaceutical Main Business
Table 123. Grand Pharmaceutical Latest Developments
Table 124. Telix Pharmaceuticals Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 125. Telix Pharmaceuticals PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 126. Telix Pharmaceuticals PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Telix Pharmaceuticals Main Business
Table 128. Telix Pharmaceuticals Latest Developments
Table 1. PSMA-labeled Imaging Ligands Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. PSMA-labeled Imaging Ligands Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Gallium-68?Ga-68?
Table 4. Major Players of Fluorine-18?F-18?
Table 5. Global PSMA-labeled Imaging Ligands Sales by Type (2021-2026) & (Units)
Table 6. Global PSMA-labeled Imaging Ligands Sales Market Share by Type (2021-2026)
Table 7. Global PSMA-labeled Imaging Ligands Revenue by Type (2021-2026) & ($ million)
Table 8. Global PSMA-labeled Imaging Ligands Revenue Market Share by Type (2021-2026)
Table 9. Global PSMA-labeled Imaging Ligands Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Ready-to-use Drug
Table 11. Major Players of Kit-based Radiolabeling
Table 12. Global PSMA-labeled Imaging Ligands Sales by Dosage (2021-2026) & (Units)
Table 13. Global PSMA-labeled Imaging Ligands Sales Market Share by Dosage (2021-2026)
Table 14. Global PSMA-labeled Imaging Ligands Revenue by Dosage (2021-2026) & ($ million)
Table 15. Global PSMA-labeled Imaging Ligands Revenue Market Share by Dosage (2021-2026)
Table 16. Global PSMA-labeled Imaging Ligands Sale Price by Dosage (2021-2026) & (US$/Unit)
Table 17. Global PSMA-labeled Imaging Ligands Sale by Application (2021-2026) & (Units)
Table 18. Global PSMA-labeled Imaging Ligands Sale Market Share by Application (2021-2026)
Table 19. Global PSMA-labeled Imaging Ligands Revenue by Application (2021-2026) & ($ million)
Table 20. Global PSMA-labeled Imaging Ligands Revenue Market Share by Application (2021-2026)
Table 21. Global PSMA-labeled Imaging Ligands Sale Price by Application (2021-2026) & (US$/Unit)
Table 22. Global PSMA-labeled Imaging Ligands Sales by Company (2021-2026) & (Units)
Table 23. Global PSMA-labeled Imaging Ligands Sales Market Share by Company (2021-2026)
Table 24. Global PSMA-labeled Imaging Ligands Revenue by Company (2021-2026) & ($ millions)
Table 25. Global PSMA-labeled Imaging Ligands Revenue Market Share by Company (2021-2026)
Table 26. Global PSMA-labeled Imaging Ligands Sale Price by Company (2021-2026) & (US$/Unit)
Table 27. Key Manufacturers PSMA-labeled Imaging Ligands Producing Area Distribution and Sales Area
Table 28. Players PSMA-labeled Imaging Ligands Products Offered
Table 29. PSMA-labeled Imaging Ligands Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 30. New Products and Potential Entrants
Table 31. Market M&A Activity & Strategy
Table 32. Global PSMA-labeled Imaging Ligands Sales by Geographic Region (2021-2026) & (Units)
Table 33. Global PSMA-labeled Imaging Ligands Sales Market Share Geographic Region (2021-2026)
Table 34. Global PSMA-labeled Imaging Ligands Revenue by Geographic Region (2021-2026) & ($ millions)
Table 35. Global PSMA-labeled Imaging Ligands Revenue Market Share by Geographic Region (2021-2026)
Table 36. Global PSMA-labeled Imaging Ligands Sales by Country/Region (2021-2026) & (Units)
Table 37. Global PSMA-labeled Imaging Ligands Sales Market Share by Country/Region (2021-2026)
Table 38. Global PSMA-labeled Imaging Ligands Revenue by Country/Region (2021-2026) & ($ millions)
Table 39. Global PSMA-labeled Imaging Ligands Revenue Market Share by Country/Region (2021-2026)
Table 40. Americas PSMA-labeled Imaging Ligands Sales by Country (2021-2026) & (Units)
Table 41. Americas PSMA-labeled Imaging Ligands Sales Market Share by Country (2021-2026)
Table 42. Americas PSMA-labeled Imaging Ligands Revenue by Country (2021-2026) & ($ millions)
Table 43. Americas PSMA-labeled Imaging Ligands Sales by Type (2021-2026) & (Units)
Table 44. Americas PSMA-labeled Imaging Ligands Sales by Application (2021-2026) & (Units)
Table 45. APAC PSMA-labeled Imaging Ligands Sales by Region (2021-2026) & (Units)
Table 46. APAC PSMA-labeled Imaging Ligands Sales Market Share by Region (2021-2026)
Table 47. APAC PSMA-labeled Imaging Ligands Revenue by Region (2021-2026) & ($ millions)
Table 48. APAC PSMA-labeled Imaging Ligands Sales by Type (2021-2026) & (Units)
Table 49. APAC PSMA-labeled Imaging Ligands Sales by Application (2021-2026) & (Units)
Table 50. Europe PSMA-labeled Imaging Ligands Sales by Country (2021-2026) & (Units)
Table 51. Europe PSMA-labeled Imaging Ligands Revenue by Country (2021-2026) & ($ millions)
Table 52. Europe PSMA-labeled Imaging Ligands Sales by Type (2021-2026) & (Units)
Table 53. Europe PSMA-labeled Imaging Ligands Sales by Application (2021-2026) & (Units)
Table 54. Middle East & Africa PSMA-labeled Imaging Ligands Sales by Country (2021-2026) & (Units)
Table 55. Middle East & Africa PSMA-labeled Imaging Ligands Revenue Market Share by Country (2021-2026)
Table 56. Middle East & Africa PSMA-labeled Imaging Ligands Sales by Type (2021-2026) & (Units)
Table 57. Middle East & Africa PSMA-labeled Imaging Ligands Sales by Application (2021-2026) & (Units)
Table 58. Key Market Drivers & Growth Opportunities of PSMA-labeled Imaging Ligands
Table 59. Key Market Challenges & Risks of PSMA-labeled Imaging Ligands
Table 60. Key Industry Trends of PSMA-labeled Imaging Ligands
Table 61. PSMA-labeled Imaging Ligands Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. PSMA-labeled Imaging Ligands Distributors List
Table 64. PSMA-labeled Imaging Ligands Customer List
Table 65. Global PSMA-labeled Imaging Ligands Sales Forecast by Region (2027-2032) & (Units)
Table 66. Global PSMA-labeled Imaging Ligands Revenue Forecast by Region (2027-2032) & ($ millions)
Table 67. Americas PSMA-labeled Imaging Ligands Sales Forecast by Country (2027-2032) & (Units)
Table 68. Americas PSMA-labeled Imaging Ligands Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. APAC PSMA-labeled Imaging Ligands Sales Forecast by Region (2027-2032) & (Units)
Table 70. APAC PSMA-labeled Imaging Ligands Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 71. Europe PSMA-labeled Imaging Ligands Sales Forecast by Country (2027-2032) & (Units)
Table 72. Europe PSMA-labeled Imaging Ligands Revenue Forecast by Country (2027-2032) & ($ millions)
Table 73. Middle East & Africa PSMA-labeled Imaging Ligands Sales Forecast by Country (2027-2032) & (Units)
Table 74. Middle East & Africa PSMA-labeled Imaging Ligands Revenue Forecast by Country (2027-2032) & ($ millions)
Table 75. Global PSMA-labeled Imaging Ligands Sales Forecast by Type (2027-2032) & (Units)
Table 76. Global PSMA-labeled Imaging Ligands Revenue Forecast by Type (2027-2032) & ($ millions)
Table 77. Global PSMA-labeled Imaging Ligands Sales Forecast by Application (2027-2032) & (Units)
Table 78. Global PSMA-labeled Imaging Ligands Revenue Forecast by Application (2027-2032) & ($ millions)
Table 79. Lantheus Holdings Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 80. Lantheus Holdings PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 81. Lantheus Holdings PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Lantheus Holdings Main Business
Table 83. Lantheus Holdings Latest Developments
Table 84. Novartis Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 85. Novartis PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 86. Novartis PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Novartis Main Business
Table 88. Novartis Latest Developments
Table 89. Curium Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 90. Curium PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 91. Curium PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Curium Main Business
Table 93. Curium Latest Developments
Table 94. Blue Earth Diagnostics Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 95. Blue Earth Diagnostics PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 96. Blue Earth Diagnostics PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Blue Earth Diagnostics Main Business
Table 98. Blue Earth Diagnostics Latest Developments
Table 99. Bayer Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 100. Bayer PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 101. Bayer PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Bayer Main Business
Table 103. Bayer Latest Developments
Table 104. Advanced Biochemical Compounds(ABX) Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 105. Advanced Biochemical Compounds(ABX) PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 106. Advanced Biochemical Compounds(ABX) PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Advanced Biochemical Compounds(ABX) Main Business
Table 108. Advanced Biochemical Compounds(ABX) Latest Developments
Table 109. Yantai Dongcheng Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 110. Yantai Dongcheng PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 111. Yantai Dongcheng PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Yantai Dongcheng Main Business
Table 113. Yantai Dongcheng Latest Developments
Table 114. China Isotope & Radiation Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 115. China Isotope & Radiation PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 116. China Isotope & Radiation PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. China Isotope & Radiation Main Business
Table 118. China Isotope & Radiation Latest Developments
Table 119. Grand Pharmaceutical Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 120. Grand Pharmaceutical PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 121. Grand Pharmaceutical PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Grand Pharmaceutical Main Business
Table 123. Grand Pharmaceutical Latest Developments
Table 124. Telix Pharmaceuticals Basic Information, PSMA-labeled Imaging Ligands Manufacturing Base, Sales Area and Its Competitors
Table 125. Telix Pharmaceuticals PSMA-labeled Imaging Ligands Product Portfolios and Specifications
Table 126. Telix Pharmaceuticals PSMA-labeled Imaging Ligands Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Telix Pharmaceuticals Main Business
Table 128. Telix Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of PSMA-labeled Imaging Ligands
Figure 2. PSMA-labeled Imaging Ligands Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PSMA-labeled Imaging Ligands Sales Growth Rate 2021-2032 (Units)
Figure 7. Global PSMA-labeled Imaging Ligands Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. PSMA-labeled Imaging Ligands Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. PSMA-labeled Imaging Ligands Sales Market Share by Country/Region (2025)
Figure 10. PSMA-labeled Imaging Ligands Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Gallium-68?Ga-68?
Figure 12. Product Picture of Fluorine-18?F-18?
Figure 13. Global PSMA-labeled Imaging Ligands Sales Market Share by Type in 2026
Figure 14. Global PSMA-labeled Imaging Ligands Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Ready-to-use Drug
Figure 16. Product Picture of Kit-based Radiolabeling
Figure 17. Global PSMA-labeled Imaging Ligands Sales Market Share by Dosage in 2026
Figure 18. Global PSMA-labeled Imaging Ligands Revenue Market Share by Dosage (2021-2026)
Figure 19. PSMA-labeled Imaging Ligands Consumed in Initial Staging
Figure 20. Global PSMA-labeled Imaging Ligands Market: Initial Staging (2021-2026) & (Units)
Figure 21. PSMA-labeled Imaging Ligands Consumed in Biochemical Recurrence
Figure 22. Global PSMA-labeled Imaging Ligands Market: Biochemical Recurrence (2021-2026) & (Units)
Figure 23. PSMA-labeled Imaging Ligands Consumed in Theranostics Selection
Figure 24. Global PSMA-labeled Imaging Ligands Market: Theranostics Selection (2021-2026) & (Units)
Figure 25. PSMA-labeled Imaging Ligands Consumed in Others
Figure 26. Global PSMA-labeled Imaging Ligands Market: Others (2021-2026) & (Units)
Figure 27. Global PSMA-labeled Imaging Ligands Sale Market Share by Application (2025)
Figure 28. Global PSMA-labeled Imaging Ligands Revenue Market Share by Application in 2025
Figure 29. PSMA-labeled Imaging Ligands Sales by Company in 2025 (Units)
Figure 30. Global PSMA-labeled Imaging Ligands Sales Market Share by Company in 2025
Figure 31. PSMA-labeled Imaging Ligands Revenue by Company in 2025 ($ millions)
Figure 32. Global PSMA-labeled Imaging Ligands Revenue Market Share by Company in 2025
Figure 33. Global PSMA-labeled Imaging Ligands Sales Market Share by Geographic Region (2021-2026)
Figure 34. Global PSMA-labeled Imaging Ligands Revenue Market Share by Geographic Region in 2025
Figure 35. Americas PSMA-labeled Imaging Ligands Sales 2021-2026 (Units)
Figure 36. Americas PSMA-labeled Imaging Ligands Revenue 2021-2026 ($ millions)
Figure 37. APAC PSMA-labeled Imaging Ligands Sales 2021-2026 (Units)
Figure 38. APAC PSMA-labeled Imaging Ligands Revenue 2021-2026 ($ millions)
Figure 39. Europe PSMA-labeled Imaging Ligands Sales 2021-2026 (Units)
Figure 40. Europe PSMA-labeled Imaging Ligands Revenue 2021-2026 ($ millions)
Figure 41. Middle East & Africa PSMA-labeled Imaging Ligands Sales 2021-2026 (Units)
Figure 42. Middle East & Africa PSMA-labeled Imaging Ligands Revenue 2021-2026 ($ millions)
Figure 43. Americas PSMA-labeled Imaging Ligands Sales Market Share by Country in 2025
Figure 44. Americas PSMA-labeled Imaging Ligands Revenue Market Share by Country (2021-2026)
Figure 45. Americas PSMA-labeled Imaging Ligands Sales Market Share by Type (2021-2026)
Figure 46. Americas PSMA-labeled Imaging Ligands Sales Market Share by Application (2021-2026)
Figure 47. United States PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 48. Canada PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 49. Mexico PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 50. Brazil PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 51. APAC PSMA-labeled Imaging Ligands Sales Market Share by Region in 2025
Figure 52. APAC PSMA-labeled Imaging Ligands Revenue Market Share by Region (2021-2026)
Figure 53. APAC PSMA-labeled Imaging Ligands Sales Market Share by Type (2021-2026)
Figure 54. APAC PSMA-labeled Imaging Ligands Sales Market Share by Application (2021-2026)
Figure 55. China PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 56. Japan PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 57. South Korea PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 58. Southeast Asia PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 59. India PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 60. Australia PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 61. China Taiwan PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 62. Europe PSMA-labeled Imaging Ligands Sales Market Share by Country in 2025
Figure 63. Europe PSMA-labeled Imaging Ligands Revenue Market Share by Country (2021-2026)
Figure 64. Europe PSMA-labeled Imaging Ligands Sales Market Share by Type (2021-2026)
Figure 65. Europe PSMA-labeled Imaging Ligands Sales Market Share by Application (2021-2026)
Figure 66. Germany PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 67. France PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 68. UK PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 69. Italy PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 70. Russia PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 71. Middle East & Africa PSMA-labeled Imaging Ligands Sales Market Share by Country (2021-2026)
Figure 72. Middle East & Africa PSMA-labeled Imaging Ligands Sales Market Share by Type (2021-2026)
Figure 73. Middle East & Africa PSMA-labeled Imaging Ligands Sales Market Share by Application (2021-2026)
Figure 74. Egypt PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 75. South Africa PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 76. Israel PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 77. Turkey PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 78. GCC Countries PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 79. Manufacturing Cost Structure Analysis of PSMA-labeled Imaging Ligands in 2026
Figure 80. Manufacturing Process Analysis of PSMA-labeled Imaging Ligands
Figure 81. Industry Chain Structure of PSMA-labeled Imaging Ligands
Figure 82. Channels of Distribution
Figure 83. Global PSMA-labeled Imaging Ligands Sales Market Forecast by Region (2027-2032)
Figure 84. Global PSMA-labeled Imaging Ligands Revenue Market Share Forecast by Region (2027-2032)
Figure 85. Global PSMA-labeled Imaging Ligands Sales Market Share Forecast by Type (2027-2032)
Figure 86. Global PSMA-labeled Imaging Ligands Revenue Market Share Forecast by Type (2027-2032)
Figure 87. Global PSMA-labeled Imaging Ligands Sales Market Share Forecast by Application (2027-2032)
Figure 88. Global PSMA-labeled Imaging Ligands Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of PSMA-labeled Imaging Ligands
Figure 2. PSMA-labeled Imaging Ligands Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PSMA-labeled Imaging Ligands Sales Growth Rate 2021-2032 (Units)
Figure 7. Global PSMA-labeled Imaging Ligands Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. PSMA-labeled Imaging Ligands Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. PSMA-labeled Imaging Ligands Sales Market Share by Country/Region (2025)
Figure 10. PSMA-labeled Imaging Ligands Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Gallium-68?Ga-68?
Figure 12. Product Picture of Fluorine-18?F-18?
Figure 13. Global PSMA-labeled Imaging Ligands Sales Market Share by Type in 2026
Figure 14. Global PSMA-labeled Imaging Ligands Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Ready-to-use Drug
Figure 16. Product Picture of Kit-based Radiolabeling
Figure 17. Global PSMA-labeled Imaging Ligands Sales Market Share by Dosage in 2026
Figure 18. Global PSMA-labeled Imaging Ligands Revenue Market Share by Dosage (2021-2026)
Figure 19. PSMA-labeled Imaging Ligands Consumed in Initial Staging
Figure 20. Global PSMA-labeled Imaging Ligands Market: Initial Staging (2021-2026) & (Units)
Figure 21. PSMA-labeled Imaging Ligands Consumed in Biochemical Recurrence
Figure 22. Global PSMA-labeled Imaging Ligands Market: Biochemical Recurrence (2021-2026) & (Units)
Figure 23. PSMA-labeled Imaging Ligands Consumed in Theranostics Selection
Figure 24. Global PSMA-labeled Imaging Ligands Market: Theranostics Selection (2021-2026) & (Units)
Figure 25. PSMA-labeled Imaging Ligands Consumed in Others
Figure 26. Global PSMA-labeled Imaging Ligands Market: Others (2021-2026) & (Units)
Figure 27. Global PSMA-labeled Imaging Ligands Sale Market Share by Application (2025)
Figure 28. Global PSMA-labeled Imaging Ligands Revenue Market Share by Application in 2025
Figure 29. PSMA-labeled Imaging Ligands Sales by Company in 2025 (Units)
Figure 30. Global PSMA-labeled Imaging Ligands Sales Market Share by Company in 2025
Figure 31. PSMA-labeled Imaging Ligands Revenue by Company in 2025 ($ millions)
Figure 32. Global PSMA-labeled Imaging Ligands Revenue Market Share by Company in 2025
Figure 33. Global PSMA-labeled Imaging Ligands Sales Market Share by Geographic Region (2021-2026)
Figure 34. Global PSMA-labeled Imaging Ligands Revenue Market Share by Geographic Region in 2025
Figure 35. Americas PSMA-labeled Imaging Ligands Sales 2021-2026 (Units)
Figure 36. Americas PSMA-labeled Imaging Ligands Revenue 2021-2026 ($ millions)
Figure 37. APAC PSMA-labeled Imaging Ligands Sales 2021-2026 (Units)
Figure 38. APAC PSMA-labeled Imaging Ligands Revenue 2021-2026 ($ millions)
Figure 39. Europe PSMA-labeled Imaging Ligands Sales 2021-2026 (Units)
Figure 40. Europe PSMA-labeled Imaging Ligands Revenue 2021-2026 ($ millions)
Figure 41. Middle East & Africa PSMA-labeled Imaging Ligands Sales 2021-2026 (Units)
Figure 42. Middle East & Africa PSMA-labeled Imaging Ligands Revenue 2021-2026 ($ millions)
Figure 43. Americas PSMA-labeled Imaging Ligands Sales Market Share by Country in 2025
Figure 44. Americas PSMA-labeled Imaging Ligands Revenue Market Share by Country (2021-2026)
Figure 45. Americas PSMA-labeled Imaging Ligands Sales Market Share by Type (2021-2026)
Figure 46. Americas PSMA-labeled Imaging Ligands Sales Market Share by Application (2021-2026)
Figure 47. United States PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 48. Canada PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 49. Mexico PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 50. Brazil PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 51. APAC PSMA-labeled Imaging Ligands Sales Market Share by Region in 2025
Figure 52. APAC PSMA-labeled Imaging Ligands Revenue Market Share by Region (2021-2026)
Figure 53. APAC PSMA-labeled Imaging Ligands Sales Market Share by Type (2021-2026)
Figure 54. APAC PSMA-labeled Imaging Ligands Sales Market Share by Application (2021-2026)
Figure 55. China PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 56. Japan PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 57. South Korea PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 58. Southeast Asia PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 59. India PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 60. Australia PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 61. China Taiwan PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 62. Europe PSMA-labeled Imaging Ligands Sales Market Share by Country in 2025
Figure 63. Europe PSMA-labeled Imaging Ligands Revenue Market Share by Country (2021-2026)
Figure 64. Europe PSMA-labeled Imaging Ligands Sales Market Share by Type (2021-2026)
Figure 65. Europe PSMA-labeled Imaging Ligands Sales Market Share by Application (2021-2026)
Figure 66. Germany PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 67. France PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 68. UK PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 69. Italy PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 70. Russia PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 71. Middle East & Africa PSMA-labeled Imaging Ligands Sales Market Share by Country (2021-2026)
Figure 72. Middle East & Africa PSMA-labeled Imaging Ligands Sales Market Share by Type (2021-2026)
Figure 73. Middle East & Africa PSMA-labeled Imaging Ligands Sales Market Share by Application (2021-2026)
Figure 74. Egypt PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 75. South Africa PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 76. Israel PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 77. Turkey PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 78. GCC Countries PSMA-labeled Imaging Ligands Revenue Growth 2021-2026 ($ millions)
Figure 79. Manufacturing Cost Structure Analysis of PSMA-labeled Imaging Ligands in 2026
Figure 80. Manufacturing Process Analysis of PSMA-labeled Imaging Ligands
Figure 81. Industry Chain Structure of PSMA-labeled Imaging Ligands
Figure 82. Channels of Distribution
Figure 83. Global PSMA-labeled Imaging Ligands Sales Market Forecast by Region (2027-2032)
Figure 84. Global PSMA-labeled Imaging Ligands Revenue Market Share Forecast by Region (2027-2032)
Figure 85. Global PSMA-labeled Imaging Ligands Sales Market Share Forecast by Type (2027-2032)
Figure 86. Global PSMA-labeled Imaging Ligands Revenue Market Share Forecast by Type (2027-2032)
Figure 87. Global PSMA-labeled Imaging Ligands Sales Market Share Forecast by Application (2027-2032)
Figure 88. Global PSMA-labeled Imaging Ligands Revenue Market Share Forecast by Application (2027-2032)
